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Abstract
Adaptive evolution is characterized by positive and parallel, or repeated selection of mutations. Mouse adaptation of
influenza A virus (IAV) produces virulent mutants that demonstrate positive and parallel evolution of mutations in the
hemagglutinin (HA) receptor and non-structural protein 1 (NS1) interferon antagonist genes. We now present a genomic
analysis of all 11 genes of 39 mouse adapted IAV variants from 10 replicate adaptation experiments. Mutations were
mapped on the primary and structural maps of each protein and specific mutations were validated with respect to
virulence, replication, and RNA polymerase activity. Mouse adapted (MA) variants obtained after 12 or 20–21 serial infections
acquired on average 5.8 and 7.9 nonsynonymous mutations per genome of 11 genes, respectively. Among a total of 115
nonsynonymous mutations, 51 demonstrated properties of natural selection including 27 parallel mutations. The greatest
degree of parallel evolution occurred in the HA receptor and ribonucleocapsid components, polymerase subunits (PB1, PB2,
PA) and NP. Mutations occurred in host nuclear trafficking factor binding sites as well as sites of virus-virus protein subunit
interaction for NP, NS1, HA and NA proteins. Adaptive regions included cap binding and endonuclease domains in the PB2
and PA polymerase subunits. Four mutations in NS1 resulted in loss of binding to the host cleavage and polyadenylation
specificity factor (CPSF30) suggesting that a reduction in inhibition of host gene expression was being selected. The most
prevalent mutations in PB2 and NP were shown to increase virulence but differed in their ability to enhance replication and
demonstrated epistatic effects. Several positively selected RNA polymerase mutations demonstrated increased virulence
associated with .300% enhanced polymerase activity. Adaptive mutations that control host range and virulence were
identified by their repeated selection to comprise a defined model for studying IAV evolution to increased virulence in the
mouse.
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Introduction
The mutational basis for the control of host switching (host-
specific infection) and virulence (disease severity) in influenza A
viruses (IAV) or their interrelationship is poorly understood [1–4]
and the identification of genetic markers of host adaptation is the
subject of much debate [5]. The existing knowledge of the
evolution of virulence and host switching in IAV is incomplete as
recently demonstrated by the introduction of a novel H1N1 IAV
from swine into humans without the genetic markers associated
with virulence and interspecies transmission [6–8]. Because
virulence in IAV is controlled by mutations in multiple genes
(see below) and novel virulent IAV rarely possess the same genetic
markers, it is apparent that there are multiple genetic pathways for
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21740virulence and host-switching. Fundamental questions remain
about the IAV adaptive mutations that modulate infection and
disease, such as their identity, number, and repeatability of
occurrence. Experimental studies of mouse adaptation (MA) of
IAV identify parallel adaptive mutations that involve the repeated
selection of mutation sites in HA and NS1genes among viruses
from independent MA experiments [9,10]. Parallel evolution is
characteristic of drug resistance and is increasingly being observed
among organisms that have evolved common traits ([11–13]. We
now extend these studies of parallel evolution by performing full
genomic sequence analysis of MA variants with mapping of all 11
viral proteins listed in Table 1. However, the links between IAV
evolution, adaptation and virulence have yet to be elucidated.
IAV are enveloped with genomes composed of 8 negative sense
RNA segments encoding 11 proteins (Table 1). IAV replication
requires an ability to overcome host resistance and establish a
productive infection that is achieved by entering cells to express
genes that function to replicate and assemble genomes into virus
particles. Replication also entails extensive interactions among
viral proteins as well as host-factors [14]. Genome wide screens
have identified 1,449 host proteins that are required for IAV
replication [15] and a recent protein interaction analysis has
identified 87 virus-host and 31 virus-virus protein interactions
[16], however the binding sites of only a minority of these
interactions are known [17–19]. Because replication occurs in the
nucleus, the sites of interaction with host nuclear import and
export proteins have been mapped for viral proteins involved in
replication (reviewed [20]). It is generally assumed that adaptation
of IAV to a non-permissive host involves mutations that overcome
deficits in interaction with host factors to restore host factor
binding such as seen for HA receptor binding to specific host sialic
acids [10,21]. Alternatively mutations affecting virus protein
subunit interactions or functions such as HA fusion may also
compensate for deficits in replication [10,21].
Mammalian IAV species originate from the migratory aquatic
bird reservoir of avian influenza viruses through processes that
include reassortment of genome segments and adaptation of
constituent genes [22]. Avian IAV species are typically non-
pathogenic however they can evolve to become highly pathogenic
strains that cause fatal infections in specific avian species [22], with
some causing fatal infections in humans as seen for the 2003
H5N1lineage [23,24]. The genetic basis for pathogenicity and host
range has been extensively studied for 1918 H1N1 pandemic [25–
28] and 1997 avian H5N1 viruses that are virulent for both
humans and mice (with mouse LD50 values of #10
3.5 pfu,
[29,30]). Genetic analyses in mice and human cells have identified
roles in pathogenesis for HA, polymerase, PB1-F2 and NS1 genes
in both 1918 H1N1 and H5N1 viruses (reviewed in [31]). The
mutational basis for the virulence properties of most of these genes
remains unknown except for sites in H5N1 HA [32] and NS1
[33,34] as well as the PB1-F2 gene of both viruses [35,36].
Adaptive evolutionary theory states that phenotypic variation
and speciation is explained by the selection of biological variants
that function to increase replicative fitness [37]. However a
complete molecular theory of adaptation is still in development
(reviewed by Orr [38]). Experimental studies of adaptation and
variation demonstrate that large phenotypic changes involve the
selection of a small number of mutations with those with the
greatest effect selected first [39]. Recent genetic studies of
bacteriophage host-range and virulence have demonstrated the
repeated selection of identical or parallel adaptive mutations for
50% of amino acid (aa) substitutions among independent
experiments [40–43]. Parallel evolution constitutes strong evidence
of natural selection as characterized for drug resistant mutants
[11,12,44].
Although phylogenic studies of humans and canine IAV show
abundant variation, evidence of positive selection is generally
lacking with nonsynonymous to synonymous mutation ratios (dN/
dS) of ,1 demonstrating stochastic variation [45–47]. However
influenza viruses demonstrate both parallel and positive Darwin-
ian evolution for mutations selected with neutralizing monoclonal
antibodies [48,49]. Antibody escape mutants are present at the
rate of 1 per 1-3610
5 infectious viruses because populations of this
size possess all single nucleotide polymorphisms (40,887 SNP’s, see
methods). In addition parallel evolution of drug resistance occurs
in the M2 ion channel and neuraminidase (NA) where S31N and
Table 1. Influenza A virus genome structure and function.
genome segment gene
a length (ntd)
b length (aa) location in virion functions
c
1 PB2 2341 759 internal transcription/capping/replication
2 PB1 2341 757 internal transcription/replication
2 PB1-F2 91 nonstructural (cellular) apoptosis
3 PA 2233 716 internal transcription/replication
4 HA 1765 565 transmembrane receptor/uncoating
5 NP 1565 498 internal RNA synthesis
6 NA 1467 469 transmembrane release
7 M1 1027 252 internal assembly/regulation
M2 97 transmembrane uncoating
8 NS1 890 237 nonstructural (cellular) IFN antagonist
NEP 121 internal nuclear export
all all 13629 4562 na
d na
Specific values are for A/Hong Kong/1/68(H3N2).
aPB2 (polymerase subunit basic 2); PB1 (polymerase subunit basic 1), PB1-F2 (PB1-frame 2); PA (polymerase subunit acidic); HA (hemagglutinin); NP (nucleocapsid); NA
(neuraminidase); M1 (matrix); M2 (M2); nonstructural 1 (NS1); nuclear export protein (NEP).
bnucleotide (ntd).
cdetails from reference[14].
dnot-applicable.
doi:10.1371/journal.pone.0021740.t001
Evolution of Virulence in Influenza A Virus
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21740H274Y mutations are diagnostic of adamantane [50] and NA
inhibitor resistance, respectively [51–53].
Although IAV are host restricted such that high dose intranasal
infection of mice with human IAV does not typically result in
disease, virulent MA variants that cause primary viral pneumonia
at low dosage can be selected by serial mouse-lung passage
(reviewed [54]). The mouse model has been shown to be relevant
for the genetic analysis of pathogenesis of avian and mammalian
IAV [55,56]. We and others have demonstrated that adaptation to
increased virulence in the mouse is associated with mutations that
increase fitness and replication in virulent mouse-adapted variants
[57–70] including the 2009 pandemic H1N1 strain [71–73]}
(Table S1). These studies have generally identified polymerase and
HA mutations as the most prominent aspect of adaptation to
increased virulence, but have identified very few adaptive
mutations in the smallest genes (NP, NA, M1/2, NS1/NEP) (see
Table S1).
Mouse adaptation of A/HK/1/68 (H3N2) (HK-wt) by 20 serial
passages in mouse lungs increased virulence by .10
5 fold
(reduction in LD50 from .10
7.7 to 10
2.7 plaque forming units
(pfu)) [59]. Significantly, on initial sequence assessment of 3 HK-
MA genomic clones plus M1/2 and NS1/NEP genes of 9 of 12
clones, we observed that 11 of 14 mutations were present in
multiple clones and therefore under positive selection [59].
Subsequent HA gene sequence analysis of 42 mouse-adapted
variants from 11 independent replicate mouse serial passage
experiments identified 25 amino acid (aa) mutations with 4 sites
demonstrating parallel evolution [10]. The observation of multiple
MA variants with the same mutation in a group of 3–6 isolates, or
alternately the same mutation in 2 virus isolates in independent
mouse-adapted populations, cannot be explained by random
chance and thus constitutes evidence of positive selection
(P#2610
28 and P#6610
27, respectively, see methods). Sequence
analysis of the NS1 gene of 42 MA variants of A/HK/1/68
identified 11 mutations with parallel evolution detected at position
106 (M106I and M106V) [9]. The parallel mutations selected in
HA and NS were adaptive; increasing virulence and growth in
mice when introduced into the HK-wt genome [9,10]. The NS1
F103L and M106I mutations had also been selected in the A/
HK/156/1997(H5N1) NS1 gene, where both mutations were
shown to be required for the virulence property of this gene in
reverse genetics studies [9]. Furthermore, reverse genetics studies
of pathogenesis of the A/HK/1/68-MA (H3N2) and A/FM/1/
47-MA (H1N1) variants, derived by serial high dose infection,
showed that all of the mutant genome segments functioned to
increase virulence in the mouse model [58,74].
In this paper we extend our previous studies of HK-wt mouse
adaptation by performing full genome sequencing of all 10
parental and 39 MA variants derived from 10 independent mouse-
adaptation experiments in order to derive genetic and protein
structural maps of adaptation to high virulence in the mouse. We
identified adaptive regions within individual viral genes that
included multiple instances of positive selection and parallel
evolution.
Results
Assessment of adaptive evolution after 12 and 20 mouse-
lung passages
We determined the nucleotide sequence of the genomes of 12
clonal isolates of HK-MA virulent variants that had been
previously obtained after 12 and 20 serial mouse infections but
only partially sequenced [59]. Sequence analysis of 6 clones
derived after passage 12 showed that each clone acquired 4 to 7
(average 5.8) nonsynonymous mutations per genome (Table 2 and
3) that were responsible for their adaptation to increased virulence,
(LD50 values of 10
5.4 to 10
3.6 pfu from [59] relative to .10
7.7 pfu
for HK-wt, (Table S2)). After 20 passages the average number of
nonsynonymous mutations of 6 clones was increased to an average
8.8 per genome (Table 2 and 3) with LD50 values from 10
4.2 to
10
2.6 pfu [59] (Table S2). Comparisons of the individual mutations
in each virus demonstrated more genetic heterogeneity at passage
12 than 20, with a trend to increased fixation of mutations within
viral populations with increasing passage number (Table 2). Novel
mutations were also selected at passage 20, including mutations in
PB2, NP, M1, M2, NS1, and NEP (Table 2). An increased
accumulation of mutations and virulence was observed with
increasing numbers of cycle of serial mouse infections. The MA
populations were under strong selection as evidenced by high
nonsynonymous to synonymous (dN/dS) ratios for each virus; with
an average of 2.8 for both the passage 12 and 20 virus groups
(Table 3). Because we saw a greater selection of mutations in the
smaller genes by passage 20 our subsequent mouse adaptation
experiments employed 21 passages.
Independent MA experiments demonstrate parallel
evolution
Fig. 1 illustrates the strategy used for performing multiple
independent MA experiments. Each of 9 HK-wt clones was
subjected to a total of 21 mouse passages before isolating 3 MA
clones from each passage 21 population, that were then annotated
as HKMA21-population #-clone# (Fig. 1). Viral stocks of the 9
HK-wt subclones provided viral populations that originated from
individual virus particles (HK-wt subclones) and thus the selection
of mutations in these populations constitutes independent events
relative to those mutations characterized in the passage HKMA12
and 20 populations (Table 2).
The genomes of each HK-wt subclone as well as each of the 27
HKMA21 variants was subjected to full genome sequencing to
identify mutations selected on mouse-adaptation (Genbank
numbers in Table S9). Only one coding mutation and 8
synonymous mutations were found among the 9 subclones of
HK-wt (Table S3, S4, S5, S6, S7, S8) indicating that each genome
possessed an average of 1 single nucleotide polymorphism that
defined the parental sequence used to initiate infections in the 9
independent MA series. Comparison of the gene sequences of 27
HKMA21 clones with their corresponding HK-wt clones
identified an average of 7.7 non-synonymous mutations per MA
genome (Table S2). Of the 429 sequenced MA genes (from 39 MA
viruses) most possessed 0 or 1 mutations (45 and 42% respectively)
with 2 or 3 mutations in 11 and 1.4% respectively (Table S2). The
HA and PB2 genes acquired the most mutations on average, 1.54
and 1.38 respectively, with most mutations selected in the
ribonucleocapsid complex of genes (PB2+PB1+PA+NP) that
possessed an average of 4.33 mutations per genome, relative to
the remainder of the genome (HA+NA+M1+M2+NS1+NEP+
PB1-F2 genes) that possessed an average of 3.23 mutations per
genome (Table S2). The LD50 values for 7 of the 27 MA21
variants ranged from 10
1.1 to 10
6.5 pfu (Table S2).
PB2 protein
Genome segments of each MA21 derivative were aligned with
respect to the coding sequence for each parental strain to identify
mutations (Tables S3, S4, S5, S6, S7, S8). Sequence comparison of
the MA PB2 genes showed that 100% of the MA strains possessed
mutations with 1 to 3 coding substitutions each (Table 2 and S3).
Parallel evolution was seen for the D701N, D740N and K482R
mutations that were obtained in 6, 4, and 2 populations
Evolution of Virulence in Influenza A Virus
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selected, found in 25 and 7 of 39 clones, respectively (Table 2 and
S3). Positive selection as evident by the isolation of multiple mutants
with the same mutation from the same population was also seen for
3 other mutations: V480I, E249G and S286G (shown in red in
Table S3). PB2 mutations clustered in regions on both the primary
(Fig. 2) and 3D structure maps (Fig. 3), involving the nuclear
localization signal (NLS) and cap binding domains. PB2 mutations
between position 249 and 569 reside in the host 7methyl guanosine
cap binding domain with the R355M and V421 mutations in
contact with the cap phosphate as well as in a solvent exposed loop
of PB2, respectively [75] (Fig. 3A). PB2 mutations between 554 and
Table 2. Mutations in genomes of mouse-adapted variants obtained after 12 and 20 mouse-lung passages relative to HK-wt.
HKMA12 clones and mutations HKMA20 clones and mutations
gene HK-wt
a 12
b 12A 12B 12C 12D 12E 20
b 20A 20B 20C
a 20D 20E positive selection
PB2 D701 N N N NNNNNNNNNy e s
D740 NNNNNNNN NNNNnd
PB1 R190 NNNNNNK NNNNNnd
K578 N T NNT N T NNNT N yes
PA D27 G NNG NNNNNNNNyes
Q556 NNNNNRRRRRRRy e s
E610 NNG NNNNNNNNNnd
K673 NNR NNNNNNNNNnd
HA
c D2
1 N Y NNNNNNNNNNnd
P162
1 NNL NNNNNNNNNnd
G218
1 W NNWWWWWWWWWy e s
N246
1 N D NNNNNNNNNNnd
N154
2 NNNNNNNNNNS N yes
T156
2 N NNNNN NNNNN N yes
D158
2 NNN NNNNNNNNNnd
N P D 3 4 NNNNNNNNNNNNy e s
D480 NNNNNNNNNNNN yes
NA A110 NNNNNNNNNNV N nd
P468 H H H H NNH N HHN H yes
M1
b D232 NNNNNNNNNNNNyes
M2
b D44 NNNNNNNNNN. Ny e s
NS1
a V23 NNNNA N AANNNNyes
F103 NNNNNNNNLLLN yes
NEP
a K88 NNNNNNNNR NNNnd
apreviously independently sequenced in [59].
bpartially independently sequenced as reported in [59].
cmutation found in multiple clones is indicated (yes) versus not-detected (nd).
dindependently sequenced in [10].
eHA mutations in the HA1 and HA2 subunits are indicated with superscripts 1 and 2 respectively.
fidentity to HK-wt amino acids is indicated by dots.
gsame loss of glycosylation as HA T156
2N.
doi:10.1371/journal.pone.0021740.t002
Table 3. Assessment of nonsynonymous (dN) versus synonymous (dS) nucleotide changes (ntd), are shown for HKMA12 and
HKMA20 variants relative to HK-wt.
HKMA12 clones HKMA20 clones
genome values HK-wt 12 12A 12B 12C 12D 12E 20 20A 20B 20C 20D 20E average
total ntd change 0 9 10 9 9 7 6 14 12 14 12 11 10 10.3
t o t a l d N 0 6 676641 0 81 0 9977 . 3
t o t a l d S 0 3 423124 443232 . 9
dN/dS 0 2.0 1.5 3.5 2.0 6.0 2.0 2.5 2.0 2.5 3.0 4.5 2.3 2.8
doi:10.1371/journal.pone.0021740.t003
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PB2 D701N mutation disrupts a salt bridge with R753 that
sequesters the nuclear localization signal to result in NLS release
(Fig. 3C). Inaddition D701Nand D740Nmutationsoccurred inthe
NLS domain that binds human importin 5a (Fig. 3D) [76].
PB1 protein
The PB1 protein was more genetically conserved than PB2 with
12 of 27 MA21 clones (44%) possessing mutations; all were single
mutations except one double mutation (Table S4). Parallel
evolution was seen at PB1 aa position 577, with 10 clones in 6
MA21 populations possessing 3 alternative mutations (K577E,
K577M or K577Q). The 577 residue is adjacent to the K578T
mutation selected in the HKMA12+20 population (Table 2) thus
defining a pair of adjacent adaptive sites that map to the center of
the PB2 binding site (Fig. 2). PB1 mutation R190K resides in a
nuclear localization site and a mutation at N476S maps to a site
involved in RNA polymerase activity (Fig. 2). The PB1 Q15H
mutation maps to the amino terminal PA binding region (Fig. 2)
adjacent to 14 terminal amino acids that insert into the PA binding
pocket of the PB1-PA co-crystal (Fig. 4B).
PA protein
The PA protein was highly adaptive with 24 of 27 MA21 clones
(89%) possessing 1 or 2 mutations (Table S4). Considering all PA
mutations, parallel evolution was seen for M21I, D27G, A70V,
Figure 1. Experimental design of parallel studies of mouse adaptation. The parental strain of A/Hong Kong/1/68 (HK-wt) was clonally derived
onMDCKcellsandgrowninchickenembryosbeforedilutioninPBSto1610
5 pfu/0.05 mLtoinitiateserialmousepassage;followedby20serialpassages
with 6 clones derived by plaque isolation from the passage 12 and 20 populations on MDCK cells. Replicate stocks of HK-wt (HK-#)w e r eg e n e r a t e df r o m
individual infectious virions of HK-wt by plaque isolation. Each subclone was amplified in eggs and used without dilution to infect mice ($1610
6 pfu/
0.05 mL for each mouse) to initiate 9 parallel MA series as indicated in methods before isolating 3 clones from each of the passage 21 populations.
doi:10.1371/journal.pone.0021740.g001
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localized to the PA amino-terminal domain comprised of aa 1–209
(Fig. 2 and 4A) that is involved in multiple functions, including
transcription, replication, RNA endonuclease, and cap binding
[77]. These parallel mutations as well as D3G, L16I, M21I and
V90I cluster on two surfaces of the PA amino terminal domain 3D
structure (Fig. 4A) adjacent to the nuclease active site residues
(H41, E80, D108, E119, K134 in stick model with 2 Mn
++ ions in
Fig. 4A). The S190F and S190T mutations reside in one of the
NLSs and the 556 site was adjacent to the hCLE host transcription
factor binding site [19] (Fig. 2). All 3 C-terminal mutations,
E610G, I633V, and K673R, (Table 2 and S4) mapped to sites in
the PB1 binding region (Fig. 2).
NP protein
The NP protein was mutated in 100% of MA clones with
parallel evolution seen for D34N and D290N/E mutations in 8 of
9 HKMA21 populations and 85% of the variants (23 of 27),
(Table 2 and S5). It appears that both mutation sites may affect
similar functions because they are juxtaposed on the 3D map
(Fig. 5), but reside in separate regions of primary structure that
have been involved in PB2 interaction (Fig. 2). The carboxyl
terminal mutations, M4261, A428T, V476A, D480N and D497N,
map to overlapping NP and PB2 interaction regions (Fig. 2).
Positions V476, and D480 of subunit A bind to subunit B in the
NP-trimer complex and M426I and A428T are located in the tail
loop that contacts adjacent NP molecules (Fig. 5A). The V186I
mutation is located on the surface of the RNA binding groove
(Fig. 5). The Q4K and Q20P mutations map to a NLS site binding
region (Fig. 2) but were not resolved in the crystal structure (Fig. 5).
HA protein. The HA mutations from 42 HK MA variants
have been independently sequenced and presented previously on
the 3D map of the HA monomer [10], which we have now
generated in modified form from independently derived sequence
data (data of Table S1 shown in Fig. 6 and 7A). In addition, we
present novel maps of the HA trimer and low pH form of the HA2
trimer (Fig. 7B and 7C, respectively) as well as the HA1 and HA2
primary sequence maps (Fig. 6). We observed a total of 25 HA
gene mutations involving 37 of 39 HKMA clones (Table 2 and S6)
that included 4 sites with parallel evolution (HA1 positions 162
1,
210
1, 218
1, and HA2 154
2) with 6 more showing positive selection
(G124
1D,N165
1D, S231
1N, T262
1N, T156
2N, and D160
2N). The
mutations were clustered in 2 regions of the primary and 3D maps.
One region in HA1 (Fig. 6) defined a HA1-HA1 contact face
adjacent to the receptor binding site and the 165
1 glycosylation site
(Fig. 7A and C). The second adaptive region was around the 154
2
Figure 2. Mouse adaptive mutations on the primary structural maps of PB2, PB1, PA and NP proteins. The amino acid location of
mutations are numbered and indicated with arrowheads on the linear sequence, sites of positive selection are shown red and parallel mutations are
additionally indicated with an asterisk and the number of populations in parenthesis. The locations of regions of interaction, or functions are
indicated with rectangles and are labeled with respect to interacting viral proteins as indicated in Methods. Nuclear localization signals (NLS) arei n
black, and host protein sites are indicated for PB2, PA and NP; PB1 polymerase activity regions are in purple and PB2 cap binding regions are in
orange. hCLE, the human transcription factor is positioned In PA according to [124] The following mutations were mapped previously: PB2 D701N, PA
Q556R, NP D34N, and NP D480N[59].
doi:10.1371/journal.pone.0021740.g002
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between positions 154 to 160 that aligned on a loop extending to
the transmembrane region in the low pH form of HA2 (Fig. 6 and
7B).
NA Protein
The NA protein was mutated in 18 of 27 (67%) MA21 clones
(Table S7 and 2). Parallel evolution was seen at position 110
(MA21-5-1 and MA20) and positive selection was observed for
mutations at sites 20 and 176. The mutations formed 2 groups on
the primary sequence map that were in the amino terminal half of
the protein including the transmembrane domain, and in the C-
terminal region (Fig. 6). On the 3D structural maps, the mutations
primarily localized on the top surface around the sialic acid
binding and glycosylation sites as well as contacts with adjacent
NA monomers in the tetrameric structure (Fig. 8).
M1 and M2 protein
M1 and M2 are overlapping genes encoded in different reading
frames. Both were highly conserved among MA21 clones; with 3
and 4 variants, respectively (Table S8 and 2). M1 mutations
showed positive selection for 2 of 3 sites in the C-terminal region of
unsolved 3D structure between residues 198 and 232 in a region
that has been shown to bind ribonucleoprotein (RNP) (Fig. 6).
Only 3 mutations were observed in the M2 protein, at position 26
and 32 and the positively selected mutation at 44, all of which
resided in or near the ion channel domain (Table 2 and S8;
Fig. 9A). All 3 clones of the HKMA21-12 population possessed an
M2 L26F mutation that was present in the HK-12 parental clone
and thus was not selected during mouse passage (Table S8). The
mutations at residues 32 and 44 were adjacent to the same residues
of adjoining monomers in the tetrameric ion channel (Fig. 9A).
NS1 and NEP protein
NS1 and NEP are also overlapping genes encoded in different
reading frames but were more variable on mouse adaption than
the M1 and M2 proteins. Four NEP mutants were observed
among the MA21 clones and one in MA20B (Tables 2 and S8)
that were distributed along the length of the primary structure with
the positively selected S23P mutations occurring in the nuclear
export signal site (Fig. 6). The NEP G70S and E108K mutations
were adjacent to each other on the 3D structure suggesting that
they may affect a similar function (Fig. 9B).
The NS1 proteins possessed 8 mutations among 11 MA21
variants occurring as single or double mutations (Table S8) that
have been reported previously but have not been mapped [9].
Among 10 mutations that included 2 mutations in MA20 viruses,
parallel evolution was seen for M106I, and M106V and positive
selection was seen for V23A, L98S, F103L, and V180A (Table 2
and S8). The two most adaptive regions encompassed the 98, 103
and 106 sites in the middle of the protein in binding regions of the
eukaryotic translation initiation factor 4GI (eIF4GI) and the
cleavage and polyadenylation factor 4 (CPSF30), in addition to the
M124I and D125G mutations in the PKR binding site (Fig. 6).
Figure 3. Mouse adaptive mutations on PB2 three dimensional maps. Mutation sites are shown on ribbon structures of PB2 protein with
space filling models of amino acids numbered in black for mutations found once, or red for positively selected mutations. (A) PB2 cap binding
domain bound to m7GTP (in stick image); (B) PB2 C-terminal domain with the 627 site shown in stick image. (C) PB2 NLS with R753 (stick image) that
forms a salt bridge with D701, NLS in red; (D) PB2 NLS in complex with human importin a5; NLS in red.
doi:10.1371/journal.pone.0021740.g003
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I/EIB-AP5 binding domain (Fig. 6) and mutations V180A and
R227K were found in the CPSF30 binding and PABPII binding
domains respectively (Fig. 6). Mapping the mutations on the 3D
structure of the NS1 dimer in complex with the C-terminal
CPSF30-F2F3 fragment showed that the 106 site of each NS1
monomer were in direct contact, and positions 103, 106, and 180
were in contact with CPSF30 (Fig. 10A and 10B). Each of the
mutations in contact with CPSF30 resulted in a loss of CPSF30
binding in pull-down assays of recombinant NS1 proteins
(Fig. 10C). Western blots of input levels of NS1 and CPSF30-
F2F3 are shown relative to pull down levels of anti-FLAG IgG
(Coomassie brilliant blue stained) and NS1 proteins (anti-NS1
western blot) where HK NS1-wt and the HK NS1-V23A both
bound CPSF30-F2F3 and the F103L, M106V, M106I,
M106I+L98S, and V180A did not bind CPSF30-F2F3 (Fig. 10C)
(similar data were obtained with the full length CPSF30 protein
(data not shown)). None of the recombinant NS1 proteins were
immunoprecipitated from control pull-down assays that used
empty vector transfected 293T cell lysates (data not shown). These
data indicate that mouse-adapted NS1 mutations in the CPSF30
binding site decrease CPSF30 binding which would be predicted
to reduce inhibition of mRNA processing [78].
Validation of PB2, PA and NP mutations as virulence
determinants in the mouse model
Recombinant HK-wt (rHK-wt) and mutant viruses that differed
from HK-wt due to each of the parallel PB2 mutations, K482R,
D701N, D740N, as well as D701N+D740N were generated using
reverse genetics. We assessed the ability of each of these
combinations of PB2 mutations to cause disease in groups of
mice that had been infected with each virus and monitored for
weight loss and lethality. Because the LD50 of HK-wt is .10
7.7 pfu
[59] increased mortality is not usually observed due to single
additional mutations therefore increased disease severity is
measurable by weight loss [74]. Although all mutations induced
increased weight loss (P#0.05 at day 2 post infection (pi) and
P,0.01 by paired t-test from day 2 to 6 for all mutants), the
greatest effect was seen for the K482R mutant. Only the D701N
mutation on its own or in combination with D740N resulted in
mortality (14% each), indicating that the LD50 of each mutant
virus was .5610
6 pfu (Fig. 11A and B). The D701N + D740N
mutations in combination resulted in more prolonged weight loss,
than for each mutation in isolation (Fig. 11B).
Similar infections of mice with rHK viruses that possessed the
parallel NP mutations D34N, D290N, D209E or PB2 D701N+NP
D34N showed increased lethality relative to HK-wt for the D34N
and D290N mutations (72% and 28% respectively). All mutants
had an LD50.5610
6 pfu except for D34N (LD50=2.7610
6 pfu)
that also caused a significantly reduced time to death relative to
HK-wt (#0.05 by t-test). All of these mutants enhanced disease
severity as monitored by weight loss (P#0.05 at day 2 pi and
P,0.01 by paired t-test for days 2 to 6 for all mutants) (Fig. 11C
and D). Lethality and weight loss (from day 4 to 10) was reduced
for the PB2 D701N+NP D34N mutations relative to that of NP
D34N suggesting gene interaction effects between these mutated
NP and PB2 genes.
We also tested the effect of the PA Q556R mutation on the HK-
wt backbone and the replacement of PA Q556R with HK-wt PA
on the HKMA20 backbone. Infection of groups of 5 mice with
1610
5 pfu of each virus showed that the PA Q556R mutation
resulted in significantly increased body weight loss (P#0.001 by
paired t-test) on the HK-wt backbone and a decreased time to
death (P#0.05 by t-test) in the MA20 virus relative to rMA20 +
HK PA (Fig. 11E and F). The LD50 of r-MA20 + HK PA was
10
3.8 pfu relative to the LD50 of 10
2.9 pfu for r-MA20, indicating
that the PA Q556R mutation increased virulence by 8 fold.
The effect of PB2, NP, and PA mutations on viral replication in
mouse lung was also measured at 1 dpi relative to rHK-wt by
plaque assay of lung homogenate for groups of 3 mice infected
with 5610
3 pfu. Significantly increased yields ranging from 5.8 to
43 fold more than rHK-wt was seen for NP D290N and PB2
mutations (K482R, D740N, and D701N). NP mutations D34N,
D209E, and PA Q556R did not significantly increase yields
relative to rHK-wt at this time point (Fig. 11G) nor at 3 dpi (data
not shown). Replication of the PB2 D701N+D740N was increased
whereas the PB2 D701N+NP D34N mutant was decreased
relative to PB2 D701N alone (Fig. 11G), which reflected the
Figure 4. Mouse adaptive mutations on PA and PB1 three
dimensional maps. Images are shown as in Fig. 3. A) PA N-terminal
domain with nuclease site active residues, H41, E80, D108, E119 and
K134 shown in stick diagram; manganese ions are shown with purple
spheres. (B) PA (blue) PB1 (red) complex; PA amino acids 1–14 are in
direct contact with PB2[125].
doi:10.1371/journal.pone.0021740.g004
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mice infected with these viruses (Fig. 11A–D). The NP D34N and
D290E mutations both increased disease severity but did not
significantly enhance replication indicating that their increased
virulence was replication-independent. Using reverse-genetics we
have shown that each of the 7 tested PB2, NP and PA mutations
increased virulence but that this was not proportional to
replication in the mouse lung that demonstrated epistatic effects
between PB2 and NP mutations.
The effect of PB2, PA, and NP mutations on RNA polymerase
activity was measured using the luciferase minigenome assay in
mouse B82 cells (Fig. 11H). The PB2 K482R, D701N, D740N,
and PA Q556R, all increased polymerase activity by .300%. In
addition the PB2 D701N + D740N mutations were additive to
enhance activity by .500% and thus demonstrated their adaptive
properties in mouse cells (Fig. 11H). The polymerase activities of
the NP D290N and D34N mutations were reduced or not changed
relative to HK-wt, respectively. Activity was reduced by half for
NP D34N + PB2 D701N relative to the PB2 D701N mutation
alone, demonstrating negative epistatic effects for both NP
mutations.
Because the D34N mutation was the most highly selected NP
mutation (Table 4) but reduced D701N polymerase activity we
assessed the effect to this mutation in several combinations of
polymerase mutations including those found in HKMA12 and
HKM20 clones in both mouse and human cells (Table 2). The
PB2 D701N, PB1 R190K+K578, PA Q556R, NP D34N and NP
D34N+D480N mutations were included as controls. In mouse B82
cells, all individual mutant polymerase subunits, PB2 D701N, PB1
R190K+K578T, and PA Q556R (Fig. S1A bars a-f) as well as
combinations significantly increased RNA polymerase activity by
.250% of HK–wt activity (Fig. S1A bars i-m, HKMA12E bar j,
HKMA20B, 20C and 20D bar m). The HKMA12A and 12D
(PB2 D701N + PB1 K578T + NP D34N) increased activity by
648% (P#0.05 by t-test) (Fig. S1A bar i). The PB1 K578T
mutation increased polymerase activity but the R190K mutation
did not and reduced activity when in combination with K578T
indicating epistatic effects (Fig. S1A bar c,d,e). Assaying polymer-
ase activity in human 293T cells showed increased activity to
approximately half of the levels seen in the mouse cells for the PB2
D701N and PB1 K578T, but not PA Q556R mutation (Fig. S1B).
The NP D34N mutation increased activity by about 50% in
human cells (Fig. S1B). Thus all RNA polymerase mutations
except PB1 R190K were shown to be adaptive with respect to
increased RNA polymerase activity [74].
Discussion
We extended our previous demonstration of parallel and
positive evolution in the HA and NS1 genes on IAV adaptation
to now include ribonucleocapsid components (PB1, PB2, PA, NP)
and NA proteins. In this study, we provide evidence for sites of
natural selection in all of these genes (Table 4). We observed that
serial high-dose passage of human influenza virus in the mouse
lung resulted in the positive selection of mutations. Adaptive
mutations clustered in regions of the primary (Fig. 2 and 6) and 3-
dimensional structures of viral proteins (Fig. 3–5 and 6–10). We
identified 115 mutations distributed among all influenza proteins
except PB1-F2, including 27 examples of parallel evolution that
primarily involved the polymerase subunits, NP and HA (Table 4).
Adaptive mutations were primarily located in regions of
interaction with host and in several instances involved sites of
viral subunit interaction or oligomerization (NP, NS1, HA, and
NA).
Adaptive mutations affect interaction with host proteins
and factors
Mouse adaptive mutations would be expected to affect sites of
virus-host interaction, however very few host proteins binding sites
have been mapped. As influenza virus replication is nuclear, 8
mutations were found in nuclear trafficking signals [20] of the
polymerase subunits, NP, and NEP proteins (Table 4). Mouse
Figure 5. Mouse adaptive mutations on NP protein trimer three dimensional maps. A). The mutations are shown on the asymmetric NP
trimer of subunits A (blue), B (grey) and C (gold). Mutations are shown in numbered space filling models on the ribbon backbone of subunit A with
the exception to position 480 that is shown on both subunits A and B. Mutations are numbered and shown as described in Fig. 3. Mutation sites in
contact with NP A and B subunits in the oligomer are: M426(B) to M448+E449(A); A428(B) to R261(A), V476(B) to D482+S483(A); and D480(A) to
M481(B). B). Side view of trimmer showing the clustering of mutation on alternate faces that define adaptive domains.
doi:10.1371/journal.pone.0021740.g005
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sequences are shown in bold: PB2 736-KRKR(D740N)X11KRIR-
755; PB1 187RKR(R190K)VRDNMTKKMVTQRTIGKRKQ-
R211; NP 1MAS(Q4K)GTKRSYxxM13; and NEP S23P in NES
(11DILLRMSKMQLE(S23P)) (Fig. 2 and 6) [20]. The PB2
D701N mutation disrupts a salt bridge with 753R (736-
KRKR(X12)KRIR-755) to result in unfolding of the PB2 NLS
structure, (Fig. 3C and 3D) [76] to increase PB2 NLS activity. This
is associated with increased binding to mammalian (but not avian)
importin 1a and 7a [79] and increased nuclear localization of PB2
and NP proteins [80]. This may have increased nuclear localization
activity which in turn would explain the higher polymerase activity
seen in the double mutant (PB2 D701N + D740N) (Fig. 11H). The
PB2 K482R was also independently selected in the H1N1 MA
variant A/FM/1/47-MA where it was shown to enhance virulence
(20 fold) and replication in the mouse lung [58].
Cap binding domains were primary targets for
adaptation. Both the PB2 and PA proteins demonstrated
adaptive mutations in their respective cap binding domains,
suggesting that increased ability to access host mRNA cap
complexes for priming viral transcription is important for
overcoming restricted viral replication in a new host. The N-
terminal PA cap-binding domain also possesses RNA
endonuclease, transcription, replication and protein stability
functions that may be affected by mutations in this domain [77].
Sites of virus-virus protein interaction
Influenza viruses replicate through the action of 11 genes that
interact extensively with each other and with host proteins [16].
Adaptive mutations were found to occur extensively in regions that
involved contacts with the trimetric RNA-dependent RNA
polymerase subunits as well as NP that encapsidates viral RNA
in RNP complexes (Fig. 2 and 6). Because the current maps of
viral protein interaction are largely incomplete (see [19]) it is
possible that the adaptive regions, although concurrent with virus-
virus interaction regions, are actually affecting interactions with
unknown host factors. We have previously identified adaptive HA
mutations that affect subunit interaction to raise the pH of fusion
Figure 6. Mouse adaptive mutations on the primary structural maps of HA, NA, M1, M2, NS1 and NEP proteins. Mutations are shown
as indicated for Figure 3. The locations of protein binding and active sites are indicated; RNP ribonucleocapsid protein; NLS nuclear localization signal;
NES nuclear export signal; dsRNA double-stranded RNA (aa 1–73); PABPI poly-A binding protein 1; PABPII poly-A binding protein II; RIG-I retinoic acid
inducible gene I; E1B-AP5, E1B associated protein 5; CPSF cleavage and polyadenylation specificity factor; eIF4GI eukaryotic initiation factor 4GI; and
PKR protein kinase R. The following mutations were mapped previously: HA1 G218W, HA2 T156N, NA P468H, M1 D232N, NS1 F103L + V23A, NEP K88R
[59].
doi:10.1371/journal.pone.0021740.g006
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are shown as described in Fig. 3. (A) the side view of the HA monomer composed of HA1 and HA2 (indicated with superscripts 1 and 2) with
carbohydrate side chains shown (CHO) in stick diagram is included here for reference (a similar but unglycosylated map that was generated from an
independent sequence analysis has been published [10]); (B) the low pH form of HA2; and (C) the HA trimer, top view with receptor sites indicated
with arrows.
doi:10.1371/journal.pone.0021740.g007
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proteins at sites of known viral contact in their crystal structures.
These findings indicate that adaptive mutations occur at sites
involved in viral protein interactions and oligomerization and may
affect properties associated with these interactions (Fig. 2, 5, 7, 8,
and 10). The RNA polymerizing subunit, PB1, that binds PB2 and
PA, had an adaptive region defined by adjacent amino acid
mutations K577Q/E/M and K578T situated in the center of its
PB2 interaction domain (Fig. 2). The PB1 Q15H mutation
situated adjacent to the amino terminal 14 amino acids in direct
contact with the PA subunit binding-cleft could affect this
interaction (Fig. 4B). NP protein oligomerization requires contacts
mediated by the C-terminal tail linker region that was mutated at
multiple sites of NP-NP contact including M426I, A428T, V476A,
and D480N (Fig. 5). Future studies will address the roles of these
mutations in NP structure and function. The predominance of
mutations in RNP components and the increased polymerase
activity shown for some of these mutations (Fig. 11 and S1)
indicates that increased gene expression is a major driving force in
interspecies adaptive evolution. The effect of these adaptive
mutations on virus protein interactions and functions remains to
be determined.
NS1 evolution on mouse-adaptation
The NS1 protein is a multifunctional protein that binds RNA
and protein factors to antagonize IFN functions and modulate
infection [18]. NS1mutations occurred in regions that involve
binding sites for dsRNA and factors involved in post transcrip-
tional processing of host mRNA and initiation of protein synthesis
as indicated in Fig. 10. NS1mutations between position 98 and
125 with parallel evolution at position 106, involve the eIF4GI/
CPSF30 and protein kinase R (PKR) binding sites that enhance
viral replication through modification of RNA or protein factor
binding to favor viral gene expression (N. E. Forbes and E.G.
Brown in preparation). Surprisingly, earlier studies have shown
that the F103L and M106I mutations found in the first fatal
H5N1human infection in 1997 [81], resulted in a loss of ability of
NS1 to bind CPSF30 and inhibit host gene expression [82] as has
also been reported for A/PR/8/34 (H1N1) [83]and pandemic
2009 H1N1 viruses [84]. The NS1 F103L and M106I mutations
increase replication and virulence in both the A/HK/156/
1997(H5N1) and HK/1/68(H3N2) genes [9] indicating that
virulence is not dependent on an ability of NS1 to bind CPSF30.
Several of the adaptive mutations occurred at or near the sites of
NS1subunit contacts in the dimer (F103L, M106I, M106V) and
also at sites of contact of the dimer with CPSF30 (F103L, M106I,
M106V, V180A) [85], all of which resulted in loss of binding to
human CPSF30 (Fig. 10C). Although we expected that these
mutations would mediate stronger host protein binding to achieve
greater host protein shut-off, reduced CPSF30 binding may
Figure 8. Mouse adaptive mutations on NA three dimensional
maps. Mutations are shown as described in Fig. 3. (A) Mutations are
shown in the NA monomer with receptor site indicated with SA and
carbohydrate (CHO) in stick diagram; (B) the tetrameric form of NA.
doi:10.1371/journal.pone.0021740.g008
Figure 9. M2 tetramer and NEP three dimensional maps of
mouse adaptive mutations. Mutations are shown as described in
Fig. 3. (A) on the M2 tetramer and (B) the NEP protein.
doi:10.1371/journal.pone.0021740.g009
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replication which requires host mRNA derived capped oligonu-
cleotide primers [86] as well as host proteins [87]. The NS1
mutations were not selected in response to differences in mouse
CPSF30 binding site structure because human and mouse CPSF30
(CPSF subunit 4) proteins have identical sequences in the NS1-
binding domain (CPSF30-F2/F3 fragment) (Fig. S2). Thus
adaptive mutations can lead to the loss of interaction with host
proteins. Adaptive mutations therefore included those that either
enhanced (PB2 D701N and mammalian importins [79,80]; HA1
G218
1W/E and a2,3 sialic acid [10,88]) or reduced binding to
host factors such as CPSF30 (Fig. 10C).
Surface proteins
The adaptive map of the HA receptor has been previously
shown to define clusters of mutations in the HA1 subunit adjacent
to the receptor binding pocket in the HA monomer, (included here
for reference, Fig. 7A); as well as a domain in the HA2 stalk. Most
of the parallel HA mutations (P162
1S, Q210
1R, G218
1W) have
been shown to increase the pH of fusion (except T156
2N) and all
of these were associated with increased mouse cell infection and
virulence as a function of increased mouse-lung tropism and
replication [10]. The G218
2W mutation increases a2–3 sialic acid
(SA) binding, consistent with the fact that a2–3 SA linkages are the
only form of SA present in the mouse respiratory tract [89]. In
addition to the proximity of both of the HA1 and HA2 adaptive
domains to the respective 165
1 and 154
2 glycosylation sites (that
were both lost due to adaptive mutations) suggests that differences
in host mediated glycosylation may also be contributing to HA
adaptive evolution (Fig. 7) [90].
The 3D NA adaptive map demonstrated surface mutations that
surrounding the active site in the monomer and also subunit
contacts in the tetrameric structure that were also proximal to 2
glycosylated sites at aa positions 146 and 200 (Fig. 8); implicating
glycosylation and viral (NA-NA) plus host (sialic acid) factor
interactions with adaptation. NA mutations also occurred in the
C-terminal domain that has been identified in the control of acid
stability and avian to mammalian adaptation that may be involved
in mouse adaptation [91–94].
The M2 ion channel protein had mutations in the ion channel
region, including D44N that normally stabilizes the W41 gating
amino acid in the closed position[95] (by interacting with both
R45 and W41) and the I32T mutation that is adjacent to the
important hydrophilic position 31 [96]. Highly pathogenic avian
influenza virus has been identified that requires modified M2
protein to prevent premature acid activation of HA fusion in
cytoplasmic transport vesicles [97].
Mutations selected on serial mouse-lung passage were
adaptive
In addition to the validation of the adaptive roles of individual
mutations selected on serial passage (see introduction), increased
RNA polymerase activity was shown for 6 mutations: (PB1
K578T; PB2 D701N, D740N and K482R; and PA Q556R
Figure 10. NS1 three dimensional maps of mouse adaptive
mutations and effects on CPSF binding. Mutations are shown as
numbered space filling images as described in Fig. 3. (A) in the NS1
monomer; (B) the NS1 dimer effector domain (grey) bound to 2 CPSF
F2F3 fragments (dark blue). Amino acid NS1 106 of each monomer is in
direct contact in the dimer. CPSF30-F2F3 is in direct contact with NS1
amino acids 103, 106 and 180. (C) Coimmunoprecipitation of HK-wt and
V23A, F103L, M106V, M106I, M106I+L98S, and V180A mutant NS1
proteins with FLAG-CPSF30-F2/F3. Recombinant NS1 proteins (2.0 mg)
were mixed with equivalent amounts of FLAG-tagged CPSF30-F2/F3
before blotting in parallel using anti-NS1 or anti-FLAG monoclonal
antibody respectively to demonstrate the input. Pull down samples
were blotted in side-by-side comparisons for immunoglobulin (as a
loading standard) and NS1 protein to demonstrate association of NS1
with CPSF30-F2/F3.
doi:10.1371/journal.pone.0021740.g010
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Body weight and survival were monitored for groups of mice infected with recombinant HK viruses that possessed mouse adaptive mutations. (A and
B), r-HK-wt and PB2 mutants, (K482R, D701N, D740N, D701N+D740N) were used to infect groups of 4 mice with 5610
6 pfu of virus for body weight
loss and with n=7 for survival. (C and D) r-HK-wt and mutant viruses with NP mutations D34N, D290N, D209E, or PB2 D701N+NP D34N were used as
indicated to infect groups of 4 mice with 5610
6 pfu of virus and with n=7 for survival. (E and F) r-HK and r-HK + MA20-PA (Q556R) as well as r-MA20
and r-MA20 + HK-wt-PA were used to infect groups of 5 CD-1 mice with 1610
5 pfu of each with monitoring of weight loss and mortality. Weight loss
was assessed relative to r-HK-wt infections using the single sample t-test at day 2 pi or using the paired t-test for 2–6 dpi; time to death was
significant as indicated using student’s t-test, P,0.05 indicated with *. (G) Replication in mouse lungs was monitored 1 dpi after infection of groups
of 3 mice with 5610
3 pfu each. The values are means of infections yields 6SD for groups of 3 mice. (H) Polymerase activity was measured in mouse
B82 cells for each of the indicated mutations relative to luciferase minigenome expression via a mouse POL1 polymerase by HK-wt plasmids
expressing PB1, PB2, PA and NP and firefly luciferase driven by the NP promoter. Values are means 6SD for n=3 samples. Statistical significance
relative to HK-wt at the P#0.05 and P#0.01 are indicated with * and ** respectively.
doi:10.1371/journal.pone.0021740.g011
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the mouse was shown for 7 mutations: PB2 (D701N, D740N
K482R), NP (D34N, D290N, and D290E) and PA (Q556R).
These observations demonstrate that MA by serial high dose
passage is an effective method for identifying adaptive mutations.
Convergent evolution with human and animal influenza
viruses
The PB2 D701N mutation has been demonstrated in MA
variants of A/HK/1/68 [59], and H7N7 where it was shown to
increase mouse-virulence and polymerase activity [98]. The
mutation was also critical for mammalian virulence of a naturally
pathogenic avian H5N1 virus [99]. The PB2 D701N mutation has
also been observed to be selected in the human respiratory tract on
infection with HPAI H5N1 [100] with 10 occurrences of PB2
D701N or D740N mutations (6 and 4 respectively) among 154
human HPAI H5N1 infections currently recorded in GenBank
(Table S10). The PB2 D701N mutation may also have been
important for adaptation of avian H3N8 viruses to equines
because all equine viruses possess PB2 D701N. PB2 D701N has
been maintained on adaptation of equine influenza virus to dogs
with further evolution to the PB2 D701N + D740N double
mutation that may be instrumental in its continued adaptation
(Table S10). The PA T97I mutation has also evolved in parallel in
MA variants of nonpathogenic avian H5N2 and H7N3 [67], as
well as pathogenic H5N1 and H7N1 virus strains [101,102] where
it was shown to be a genetic determinant of increased virulence
and polymerase activity. The PB1 K578T mutation (Table 2)
evolved in parallel with K578Q that was a determinant of
increased virulence and polymerase activity on mouse adaptation
of A/equine/London/1416/73(H7N7)[64]. This indicates that
MA mutations are selected in multiple species including horses,
dogs and humans [100].
Conclusion
We show that a relatively small number of mutations including
those demonstrating parallel evolution mediate mouse adaptation
and increased virulence. Many mouse-adapted mutations map to
regions of interaction with both host and viral proteins. A group of
18 mutation sites were repeatedly selected and were therefore the
most adaptive (Table 4). Thus experimental mouse-adaptation
represents a predictable model system for identifying gain-of-
function mutations for the identification and characterization of
viral protein functions and interactions. Mouse adaptive models
are also useful for testing adaptive theories of evolution [4] and
supplying reference points for bioinformatics and biochemical
studies. Future studies will address the mechanisms of action and
gene interactions of adaptive mutations.
Methods
Ethics Statement
This study was carried out in compliance with the guidelines of
the Canadian Council on Animal Care (CCAC) as outlined in the
Care and Use of Experimental Animals, Vol.1, 2nd Edn. (1993),
which are recognized as ‘‘best-practices’’ by the International
Council for Laboratory Animal Science (ICLAS). The protocol
was approved by the University of Ottawa Animal Care
Committee (Protocol Number: BMI-85). Animal studies were
also performed under the supervision of a veterinarian (DVM)
and trained personnel. All efforts were made to minimize
suffering and mice were euthanized at humane end-points, if
infection resulted in greater than 25% body weight loss plus
respiratory distress.
Cells
Madin-Darby canine kidney cells (MDCK) (Health Canada,
Ottawa) were maintained in autoclavable minimum essential
medium (MEM) with Earle’s salts, and both 293T human
embryonic kidney cells (ATCC, Manassas, VA) and mouse B82
fibroblasts (Coriell Institute for Medical Research, Camden, NJ;
catalogue number GM00347) were maintained in Dulbecco’s
MEM (Invitrogen Canada Inc., Burlington). Media were supple-
mented with L-glutamine (2 mM), Penicillin (100 U/ml), Strep-
tomycin (100 ug/ml) (Invitrogen Canada Inc., Burlington) and
fetal bovine serum (FBS) (10%) (Hyclone Laboratories, Utah).
Table 4. Sites of parallel, positive and nuclear trafficking signal mouse adapted mutations.
gene sites of parallel evolution/mutations (mutants)
a postive
b total nuclear traffic signals
PB2 482(3), 701(27), 740(9) 6 17 480, 482, 701, 740 (NLS)
PB1 577/3(10) 4 8 190 (NLS)
PB1-F2 none none none none
PA 21(4), 27(4), 70(4), 97(6), 190/2(5) 7 13 190 (NLS)
NP 34(24), 290/2(14) 7 13 4 (NLS)
HA HA1:162/2(2), 210(4), 218/2(19) HA2:154/2(2)+156(8) 13 25 na
NA 110/2(2) 4 19 na
M1 none 2 3 ?
M2 none 1 2 na
NS1 106/2(6) 6 10 ?
NEP none 1 5 23 (NES)
total 17/27(39) 51 115 8
aformat - amino acid positions/number of mutations if .1 (number of mutants among 39 MA clones in parentheses).
btotal number of positive and parallel mutations.
NLS, nuclear localization signal.
NES, nuclear export signal.
na, not applicable.
doi:10.1371/journal.pone.0021740.t004
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The prototype clinical isolate A/Hong Kong/1/68 (H3N2)
(HK-wt) was obtained from the Laboratory Center for Disease
Control, Health Canada, Ottawa that was originally obtained
from H.G. Pereira (World Influenza Centre, London). The
passage history of HK-wt was: (2 passages in rhesus monkey
kidney cells) + (3 passages in chicken allantoic cavity) before 2
plaque purifications (plaque-to-plaque) on MDCK cells before
seed and stock preparation in chicken allantoic cavity. The
generation of mouse-adapted clones was described previously [59]
where 10
5 pfu HK-wt stock in 50 mL PBS was inoculated
intranasally into each of 3, 20 g CD-1 strain mice under halothane
anesthesia (3.5% halothane in O2), that were housed for 3 days
and euthanized by CO2 narcosis and surgical removal of lungs.
Lungs were pooled in 3 ml PBS and a virus extract prepared by
sonication for 2 minutes on ice, before sedimentation of debris by
centrifugation at 250 G for 5 minutes. Virus extracts were diluted
10 fold in PBS before inoculating another group of CD-1 mice
with 50 mL each with repeated passage for a total of 20 serial
passages (all lung extracts were titrated by plaque assay and
contained $5610
5 pfu of virus [24]). Clonal isolates were derived
by sequential plaque-to-plaque isolations on MDCK cells from
passage 12 (6 clones), and passage 20 (6 clones), and stocks were
prepared in MDCK cells or alternatively by a single passage in the
allantoic cavity of 10-day-old SPF chicken embryos (Canadian
Food Inspection Agency, Ottawa). MA variants were also derived
from 9 separate mouse adaption experiments that each involved
the serial passage of separate HK-wt stocks produced from HK-wt
subclones. The 9 separate HK-wt subclones were obtained by
plaque isolation from diluted HK-wt stock and used to produce 9
independent HK-wt stocks that were each used to perform 9
separate mouse passage experiments that employed 21 serial
passages each as indicated in Fig. 1. After 21 mouse passages 3
biological clones were derived from each of the 9 ‘‘MA
populations’’ by 2 sequential plaque isolations as previously
described [10] and shown in Fig. 1. The passage schedule for
each of the replicate numbered HK-wt clones (HK(clone #))
involved initial inoculation of individual mice with undiluted stock
virus (.10
6 pfu/mouse) with serial passage of undiluted lung
extract into individual mice for a total of 10 passages before 5
serial undiluted passages of 2 days each in groups of 2 mice,
followed by 6 serial undiluted passages of 3 days duration in
groups of 2 mice. In each of these passages, infected lungs were
suspended in 1 ml PBS each to make extracts that were sterilized
using 0.22 mM Millipore Millex-GV PVDF (Cork, Ireland)
filtration before serial passage that involved infection with 50 mL
of lung extract. All MA variants derived from the 9 independent
mouse-adapted passage 21 populations clones were designated as
HK(clone #) MA (mouse passage #)-(clone #).
Titration of infectivity by plaque assay
Virus stocks were subjected to serial 10 fold dilution in PBS
before application to PBS washed MDCK cells monolayers in 6
well plates as described previously [9]. Average values were
calculated for three samples that were each titrated in duplicate
plaque assays.
Calculation of median lethal dose
Median lethal dosage (LD50) of IAV variants were determined
in groups of CD-1 mice as described previously [10]. Groups of 5
female (19–21 g) CD-1 mice were infected under halothane
anesthesia (2.5% in O2) with undiluted stock virus and serial 10
fold dilutions made in PBS. Mice were monitored for survival and
weight loss over a 2 week period or until body weight increased.
Mice that lost .25% body weight and were in respiratory distress
where considered to have reached ‘‘humane endpoint’’ as required
by our animal care protocol and were euthanized by CO2
narcosis. The median lethal dose (LD50) was determined using the
Karber–Spearman method, using the formula (negative log10 of
LD50) = (negative log10 of highest dose) – (–((sum of percent
mortality at each dose/100) – 0.5)) 6log10 of dilution steps)[103].
The standard deviation of LD50 values calculated from n=3
independent assays using groups of 5 CD-1 mice, has been
determined to be 10
0.3 pfu [57].
Statistical analysis
Sample values were calculated as averages 6 standard deviation
for sample size $3 with statistical significance at the P # 0.05 level
determined using the paired or single sample, 2-tailed student’s t-
test where indicated, using the Microsoft Office ExcelH 2007 or
Graphpad PrismH v3.02 programs.
Population size required to contain all possible single
nucleotide polymorphisms (SNP)
There are 13,629 nucleotides per HK-wt genome with 3
possible substitutions at each site to yield 13,62963=40,887
SNP’s. The observed mutation rate of 1.5610
25 per nucleotide
per replication cycle [104], or ((1.5610
25) 613,629 ntds) =0.2
mutations per genome (Table 1)), therefore the total number of
40,887 SNP’s is predicted to be present in a population of 2.0610
5
infectious virions (40,887 SNP/(0.2 mutations per genome). Virus
populations of 2.0610
5 infectious viruses are expected to possess
all possible single amino acid substitution mutations (multiple
combinations of 2 or more SNP’s are too rare to be relevant to
molecular evolution [44]).
Calculation of the random probability of isolation of
multiple variants with identical mutations
Positive selection results in the increased prevalence of mutation
due to enhanced fitness versus random occurrence of the same
mutations. In analysis of positive selection the null hypothesis is
that the mutants occur at a frequency predicted by random
probability or chance. Given that prototype A/HK/1/68 virus
has a genome of 13,629 nucleotides and each position can be
substituted with 3 alternative nucleotides, there are 3 times
genome length (13,62963) or 40,887 possible SNP variants. Thus
any SNP mutant has a random probability of occurrence of 1/
40,887 and thus the probability that multiple strains of influenza
(n) will have the same mutation (SNP) is the product of the
individual probabilities times the number of samples tested (N) to
get (N/40,887)
n (see reference [44])that is P#2610
28 for 2 or
more identical mutations in a population of 6 viruses which is
much less than the significance limit of p=0.05 and thus causes
rejection of the null hypothesis in favor of positive selection.
Similarly the probability of $2 identical mutation among multiple
populations composed of 36 viruses (the largest N in this
manuscript) has P= (36/40,887) $
2 or P#2610
25 again leading
to rejection of the null hypothesis to support positive selection.
Thus the selection of $2 mutants with the same mutation in the
same or different populations is strong evidence of positive
selection indicating that the mutation was positively selected and
therefore adaptive.
Reverse genetics
HK-wt and mutants were produced using the 8 plasmid
recombineering approach with pLLB plasmids [105] as describe
previously [74].
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Viral RNA was extracted from 140 mL of stock allantoic fluid
from each virus using the QIAamp Viral RNA Mini Kit (Qiagen,
Mississauga, Ontario) and full length influenza genomic segments
were amplified [106], sequenced, and assembled as previously
described [107,108]. All Genbank accession numbers are listed in
Table S9.
RNA Polymerase assays in human and mouse cells
To compare the activities of viral RNP complexes in human
and mouse cells, a Promega Dual-Glo Luciferase Assay System
(Promega) was used [98,109]. A luciferase reporter minigenome
polymerase assay was constructed that possessed the firefly
luciferase gene driven by the human RNA POL I promoter
(phPOLI-NP-LUC) and mouse RNA POL I terminator to
generate a luciferase negative sense transcript flanked by the
influenza NP gene noncoding regions.
The phPOL1-NP-LUC plasmidwasconstructedbyinsertion of the
firefly luciferase gene and NP non-coding regions that were amplified
by PCR using pGL3 Basic (Promega, Fisher Scientific, Nepean, Ont.)
as template and the following primers: Fw: 59TATTCGTCTCAGG-
GAGCAAAAGCAGGGTAGATAATCACTCACTGAGTGAC-
ATCAAAATCATGGAAGACGCCAAAAACATA-39 Bw: 59ATA-
TCGTCTCGTATTAGTAGAAACAAGGGTATTTTTCTTTA-
CACGGCGATCTTTCCG-39.T h eP C Rp r o d u c tw a sd i g e s t e db y
BsmBI and cloned into BsmBI digested pHH21, resulting in plasmid
phPOL1-NP-LUC.
The pmPOL1-NP-LUC plasmid (mouse Polymerase I promot-
er-Luc construct) was constructed by PCR amplification of the
firefly luciferase gene flanked by NP non-coding region using the
pGL3 Basic plasmid (Promega) as template and the following
primers:Fw:59ATATCGTCTCAGGGAGCAAAAGCAGGGTA-
GATAATCACTCACTGAGTGACATCAAAATCATGGAAGA-
CGCCAAAAACAT-39,B w :5 9-TATTCGTCTCAAGGTAGTA-
GAAACAAGGGTATTTTTCTTTACACGGCGATCTTTCC-
GC-39. The PCR product was digested by BsmBI and cloned into
BsmBI digested pHL1261 [110], resulting in plasmid pmPOL1-NP-
LUC. Plasmids were sequenced to ensure there were no unwanted
mutations.
To perform the luciferase assays, 96 well plates of human 293T
or mouse B82 cells were respectively transfected with 0.06 mgo f
the reporter plasmids, phPOLI-NP-LUC or pmPOLI-NP-LUC,
in combination with 0.06 mg of each of the four pLLB-plasmids
encoding the HK-wt or mutant forms of PB2, PB1, PA, NP[105]
plus 0.06 mg of the internal control renilla luciferase expression
plasmid PRL-SV40 (Promega), using 0.5 mL of lipofectin 2000 in
100 mL of Opti-MEM (Invitrogen, Burlington, Ontario). At 48 h
post-transfection, luminescence was measured using the Promega
Dual-Glo Luciferase Assay System and a Glomax Multi Detection
System, Model 9301-010 (Fisher Scientific, Nepean, Ont.)
according to the manufacturer’s instructions. Relative luciferase
activities were calculated as the average + standard deviation of
the ratios of firefly and renilla luciferase luminescence for three
independent experiments of 3 replicates each.
Genomic mapping of mutations
Nucleotide and amino acid sequences were aligned to identify
mutations using BioEdit version 7.0.5.3 and Genedoc Multiple
sequence alignment Editor and Shading Utility version 2.7.000
software.
Linear mapping of mutations
For each influenza protein, adaptive mutations were positioned
according to their amino acid sequence location onto linear
primary structural maps that indicated known site of function or
interaction with other viral and host factors. Linear maps were
made with CorelDRAW 10 v10.410 software. The linear maps of
PB2, PB1, PA, and NP were derived from the previous maps of
Boulo et al [20] as modified by Naffakh et al., 2008 [19] with
pertinent references therein. The HA primary structure element
maps of the active site were derived from the reviews of Skehel and
Wiley [111] and Stevens et al [112]. The NA domains were
derived from the crystal structure [113] and the review of Nayak
and Jabbar [114].The M1 protein map was composed from data
in [115–119]. The M2 ion channel was mapped from data of
Lamb et al, [120]. The primary structural map of NS1 was
modified from the map of Hale et al., [18] and references therein.
The location of the NEP nuclear export signal was from [121].
Three dimensional structural maps
Structural maps were generated using the PDB ProteinWorkshop
v e r s i o n3 . 7[ 1 2 2 ]w i t hp r o t e i ns h o w ni nr i b b o nd i a g r a mw i t h
numbered mutations in space filling models. Maps used the following
structural files: PB2-(aa 535–742) PDB ID 3CW4, PB2-C-terminus
(aa 688–756) PDB ID 2GMO, PB2-C-terminus (aa 686–757) human
importin a5 co-crystal PDB ID 2JDQ; PB2-(aa 320–483)-7methy
guanosine cap co-crystal, PDB ID 2VQZ; PA (aa 257–716) bound to
amino terminus of PB1 (aa 1–16) co-crystal PDB ID 3CM8; PA
amino-terminal domain (aa 1–209) PDB ID 2W69; H3 HA (HA1
aa1–328, HA2 aa 1–175) PDB ID 1HDG; H3 low pH form (aa34–
178) PDB ID 1QU1; NP trimer (aa 8–498) PDB ID 2IGH; NA2
PDB ID 1NN2; M2-(aa 23–60) PDB ID 2KIH; NS1-(aa 1–215) PDB
ID 3F5T; NS1-(aa 85–203)-CPSF30-F2F3-(aa 56–118) co-crystal
PDB ID 2RHK; and NS2-(aa 63–116) PDB ID 1PD3.
Protein Gel Electrophoresis and Western blot
Samples were fractionated bySDS PAGE using 12.5%acrylamide
gels as described previously [57]. Western blots employed rabbit
antiserum raised against purified recombinant A/HK/1/68 NS1
protein or anti-FLAG M1 mouse monoclonal antibody (Sigma
Chemical, Burlington) and were performed as described previously
[123] but were detected with HRP conjugated goat-anti-rabbit or
goat-anti-mouse (Sigma Chemical, Burlington) respectively, and
SuperSignal West Pico chemiluminescent substrate (Pierce). Quan-
tification employed densitometry using the UN-SCAN-IT Gel
version 6.1 software (Silk Scientific Corp).
NS1 CPSF30 binding assay
Recombinant NS1 proteins with amino terminal 6xHis tags
were synthesized as described previously [123] in BL21 pLysS E.
coli using pET17b plasmids for 16 h at 21uC with 10 mM of IPTG
except that the soluble fraction was employed for purification and
was dialyzed against PBS. Purified NS1 protein was quantified
using the Bio-Rad Protein Assay and standardized by comparative
western blot. Plasmids were constructed by insertion of the NS1
genes of HK-wt and each mutant produced by PCR mutagenesis
into pET17b after PCR amplification using pfu Turbo polymerase
(Stratagene, La Jolla, CA). CPSF30 or the CPSF30-F2F3 fragment
was expressed in 1.5610
7 293T cells transfected with 30 mgo f
pCAGGS-CPSF30-Flag or pCAGGS-CPSF30-F2F3-Flag plasmid
(obtained from L. Martinez-Sobrido, Mt. Sinai school of
Medicine) in 112 ml of Lipofectamine 2000 transfection reagent
(Invitrogen, Burlington, Ont.) for 24 hrs before lysis with 100 mM
Tris, 250 mM NaCl, 0.5% NP-40, and 0.5% DOC, pH 8.5. Pull
down experiments employed the lysate from 5610
5 293 T cells,
1 ug of anti-FLAG M1 monoclonal antibody (Sigma-Aldrich,
Canada), defined amounts of NS1 protein, and 20 ml of protein G
Dyna-beads (Invitrogen, Burlington, Ont,) in a 0.25 ml volume
Evolution of Virulence in Influenza A Virus
PLoS ONE | www.plosone.org 17 June 2011 | Volume 6 | Issue 6 | e21740with rotation for 2 hr at room temperature. Beads were washed
three times in lysis buffer for 10 minutes before western blotting.
Control pull-down assays used the lysate from 5610
5 293 T cells
transfected with empty vector that did not result in NS1 pulldown
indicating a lack of nonspecific binding to anti-FLAG M1
monoclonal antibody. Similar results were obtained for both
CPSF30 or the CPSF30-F2F3 fragment pull-downs and therefore
only the CPSF-F2F3 fragment data were shown. Bound NS1
proteins were detected by western blotting with rabbit anti-NS1
antibody. Anti-FLAG M1 monoclonal antibody was monitored
after pull-down by Coomassie Brilliant Blue staining of samples
separated on 12.5% SDS-PAGE gels.
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Figure S1 RNA polymerase activity effects of PB1, PB2,
PA and NP mutations in mouse and human cells.
Polymerase activity is shown for B82 mouse cells (A) and human
293T cells (B). Mouse adaptive mutations at the indicated
positions are masked in gray and HK-wt is shown without mask
in the table aligned with bars of activity. Influenza luciferase assays
employed luciferase minigenomes expressed via a human or
mouse POL1 polymerase in mouse B82 and human 293T cells
respectively. Samples (i) has the HKMA12A and 12D combination
of mutations; (j) has HKMA12E; and (m) has the HKMA20B, C,
and D combination. Values were standardized relative to HK wt
luciferase activity as 100% and are shown as averages for n=3
experiments 6 SD. Asterisks indicates significant difference from
HK-wt polymerase activity for each cell type (* and ** indicate
P#0.05 and P#0.01 by t-test respectively).
(TIF)
Figure S2 Blast alignment of mouse CPSF30 with
human CPSF30. Amino acid sequence of mouse CPSF30
(query) is aligned above human CPSF30 sequence (Sbjct) with the
consensus sequence indicated between each sequence. The F2F3
binding fragment is indicated in yellow mask showing identical
amino acid sequence between human and mouse.
(PDF)
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